uniQure NV (NAS:QURE)
$ 15.3 8.005 (109.73%) Market Cap: 745.77 Mil Enterprise Value: -12.06 Mil PE Ratio: 0 PB Ratio: 13.30 GF Score: 75/100

Uniqure NV at Stifel CNS Days (Virtual) Transcript

Mar 28, 2023 / 03:30PM GMT
Release Date Price: $20.07 (-0.30%)
Paul Matteis
Stifel Financial Corp. - Analyst

Great. Thanks very much, everybody, for continuing on here. It's my pleasure to be moderating a chat with the CEO of uniQure, Matt Kapusta. We'll probably talk most of the time about Huntington's, but maybe I can just turn it over to Matt briefly to give us a brief update on the AMT-130 study, cadence of readouts, as well as any other quick hits in the pipeline.

So, Matt, thank you again and looking forward to the discussion.

Matt Kapusta
uniQure N.V. - CEO

Yes, Paul, thank you very much for having us here in Stifel. We really appreciate being involved in the conference. So with respect to AMT-130, just to step back, we have our two active clinical trials that are currently ongoing. One is taking place in the United States as a Phase 1/2 and the other one is taking place in Europe as a Phase 1b/2.

They're both exploring two different doses, the same two different doses. And really the only difference is that the US study is a randomized, controlled, double-blinded study with a one-year blinding

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot